This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
6ssn
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==RNASE 3/1 version3== | ==RNASE 3/1 version3== | ||
| - | <StructureSection load='6ssn' size='340' side='right'caption='[[6ssn]]' scene=''> | + | <StructureSection load='6ssn' size='340' side='right'caption='[[6ssn]], [[Resolution|resolution]] 1.51Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6SSN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6SSN FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6ssn]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6SSN OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6SSN FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ssn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ssn OCA], [https://pdbe.org/6ssn PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ssn RCSB], [https://www.ebi.ac.uk/pdbsum/6ssn PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ssn ProSAT]</span></td></tr> | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> |
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6ssn FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ssn OCA], [https://pdbe.org/6ssn PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6ssn RCSB], [https://www.ebi.ac.uk/pdbsum/6ssn PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6ssn ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Design of novel antibiotics to fight antimicrobial resistance is one of the first global health priorities. Novel protein-based strategies come out as alternative therapies. Based on the structure-function knowledge of the RNase A superfamily we have engineered a chimera that combines RNase 1 highest catalytic activity with RNase 3 unique antipathogen properties. A first construct (RNase 3/1-v1) was successfully designed with a catalytic activity 40-fold higher than RNase 3, but alas in detriment of its anti-pathogenic activity. Next, two new versions of the original chimeric protein were created showing improvement in the antimicrobial activity. Both second generation versions (RNases 3/1-v2 and -v3) incorporated a loop characteristic of RNase 3 (L7), associated to antimicrobial activity. Last, removal of an RNase 1 flexible loop (L1) in the third version enhanced its antimicrobial properties and catalytic efficiency. Here we solved the 3D structures of the three chimeras at atomic resolution by X-ray crystallography. Structural analysis outlined the key functional regions. Prediction by molecular docking of the protein chimera in complex with dinucleotides highlighted the contribution of the C-terminal region to shape the substrate binding cavity and determine the base selectivity and catalytic efficiency. Nonetheless, the structures that incorporated the key features related to RNase 3 antimicrobial activity retained the overall RNase 1 active site conformation together with the essential structural elements for binding to the human ribonuclease inhibitor (RNHI), ensuring non-cytotoxicity. Results will guide us in the design of the best RNase pharmacophore for anti-infective therapies. | ||
| + | |||
| + | Exploring the RNase A scaffold to combine catalytic and antimicrobial activities. Structural characterization of RNase 3/1 chimeras.,Fernandez-Millan P, Vazquez-Monteagudo S, Boix E, Prats-Ejarque G Front Mol Biosci. 2022 Sep 14;9:964717. doi: 10.3389/fmolb.2022.964717. , eCollection 2022. PMID:36188223<ref>PMID:36188223</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6ssn" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| + | [[Category: Synthetic construct]] | ||
[[Category: Boix E]] | [[Category: Boix E]] | ||
[[Category: Fernandez-Millan P]] | [[Category: Fernandez-Millan P]] | ||
[[Category: Prats-Ejarque G]] | [[Category: Prats-Ejarque G]] | ||
[[Category: Vazquez-Monteagudo S]] | [[Category: Vazquez-Monteagudo S]] | ||
Current revision
RNASE 3/1 version3
| |||||||||||
